Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: Additional diagnoses and avoided deaths

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1325-1334

  Neppl Huber, C ^a   Zappa, M ^b   Coebergh, J W ^c,m   Rapiti, E ^d   Rachtan, J ^e   Holleczek, B ^f   Rosso, S ^g   Aareleid, T ^h   Brenner, Hermann ^a   Gondos, A ^a   Aareleid, Tiiu ^h   Bray, Freddie ⁱ   Brewster, David H ^j   Crocetti, Emanuele ^k   Gondos, Adam ^a   Hakulinen, Timo ^l   Holleczek, Bernd ^f   Janssen Heijnen, Maryska ^m   Magi, Margit ⁿ   Rachtan, Jadwiga ^e   Zanetti, Roberto ^g   Smailyte, Giedre ^o   Usel, Massimo ^d   Zakelj, Maja Primic ^p   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d GENEVA CANCER REGISTRY   (Switzerland)

^e Cracow Cancer Registry   (Poland)

^f SAARLAND CANCER REGISTRY   (Germany)

^g Cancer Epidemiology Unit of the Centre for Cancer Epidemiology and Prevention   (Italy)

^h NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

ⁱ CANCER REGISTRY OF NORWAY   (Norway)

^j Scottish Cancer Registry   (United Kingdom)

^k Tuscany Cancer Registry   (Italy)

^l FINNISH CANCER REGISTRY   (Finland)

^m Erasmus University Rotterdam and Eindhoven Cancer Registry   (Netherlands)

ⁿ Cancer Registry of Estonia   (Estonia)

^o National Cancer Institute   (Lithuania)

^p INSTITUTE OF ONCOLOGY   (Slovenia)

more..

Author keywords

Prostate cancer; Prostate specific antigen; Registries; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; EUROPE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES;

EID: 84860476716     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr414     Document Type: Article

References (54)

1. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 2009; 53: 171-184.
2. Hankey BF, Feuer EJ, Clegg LX et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017-1024.
3. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-552.
4. Jemal A, Clegg LX, Ward E et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3-27.
5. Verdecchia A, Guzzinati S, Francisci S et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009; 45: 1042-1066.
6. Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 2005; 23: 441-447.
7. Gondos A, Bray F, Hakulinen T, Brenner H. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol 2009; 20: 564-573.
8. World cancer report 2008; Chapter 1.1. Introduction: needs and prospects for cancer control. In Boyle P, Levin B (eds), World Cancer Report 2008. Lyon, France: International Agency for Research on Cancer 2008; 12-39.
9. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
10. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-732.
11. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-990.
12. Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostatespecific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101: 374-383.
13. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-1329.
14. Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin 2009; 59: 264-273.
15. Wilt TJ, MacDonald R, Rutks I et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148: 435-448.
16. Wever EM, Draisma G, Heijnsdijk EA et al. Prostate-specific antigen screening in the United States vs in the European Randomized Study of screening for prostate cancer-Rotterdam. J Natl Cancer Inst 2010; 102: 352-355.
17. Albertsen PC. Efficacy vs effectiveness in prostate-specific antigen screening. J Natl Cancer Inst 2010; 102: 288-289.
18. Bray F, Lortet-Tieulent J, Ferlay J et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040-3052.
19. Engholm G, Ferlay J, Christensen N et al. NORDCAN - a Nordic tool for cancer information, planning, quality control and research. Acta Oncol 2010; 49(5): 725-736.
20. International Agency for Research on Cancer. (IARC). CI5 I-VIII Detailed Database. Lyon, France: IARC 2005.
21. International Agency for Research on Cancer (IARC). WHO Mortality Database. Lyon, France: IARC 2008.
22. Gondos A, Bray F, Brewster DH et al. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. Eur J Cancer 2008; 44: 1463-1475.
23. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. J Natl Cancer Inst Monogr 1961; 6: 101-121.
24. Ederer F, Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations. In Methodological note no. 10. Bethesda, MD: End Results Section, National Cancer Institute 1959.
25. Brenner H, Gefeller O, Hakulinen T. Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004; 40: 326-335.
26. Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol 2006; 164: 689-696.
27. Brenner H, Hakulinen T. Model based hybrid analysis of cancer patient survival. Eur J Cancer 2007; 43: 921-927.
28. Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patient survival. Eur J Cancer 2002; 38: 690-695.
29. Cancer Incidence in Five Continents Volumes I to IX. IARC June 2010; http://ci5.iarc.fr/CI5i-ix/glossary.htm (26 August 2011, date last accessed).
30. U.S. Census Bureau. QT-P1: Age Group and Sex: 2000.
31. Jankevicius F, Adomaitis R, Jievaltas M et al. The Launch of the Lithuanian Early Prostate Cancer Detection Program (EPCDP). Eur Urol Suppl 2007; 6(2): 174.
32. Hoffman RM, Stone SN, Hunt WC et al. Effects of misattribution in assigning cause of death on prostate cancer mortality rates. Ann Epidemiol 2003; 13: 450-454.
33. Post PN, Stockton D, Davies TW, Coebergh JW. Striking increase in incidence of prostate cancer in men aged < 60 years without improvement in prognosis. Br J Cancer 1999; 79: 13-17.
34. Merrill RM, Feuer EJ, Warren JL et al. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 1999; 150: 848-860.
35. Andren O, Garmo H, Mucci L et al. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 2009; 100: 170-173.
36. Kumar S, Shelley M, Harrison C et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006; (4): CD006019.
37. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13: 559-583.
38. Jacobs EJ, Rodriguez C, Mondul AM et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97: 975-980.
39. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010; 127(7): 1680-1691.
40. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005; 60: 543-551.
41. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008; 123: 899-904.
42. Platz EA, Leitzmann MF, Visvanathan K et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-1825.
43. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185-191.
44. D'Ambrosio GG, Campo S, Cancian M et al. Opportunistic prostate-specific antigen screening in Italy: 6 years of monitoring from the Italian general practice database. Eur J Cancer Prev 2010; 19: 413-416.
45. Drazer MW, Huo D, Schonberg MA et al. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 2011; 29: 1736-1743.
46. Zappa M, Visioli C, Crocetti E et al. Practice of opportunistic PSA screening in the Florence District. Eur J Cancer Prev 2003; 12: 201-204.
47. Zeliadt SB, Hoffman RM, Etzioni R et al. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 2011; 103: 520-523.
48. Barry MJ, Mulley AJ Jr. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important? J Natl Cancer Inst 2009; 101: 362-363.
49. Lin GA, Aaronson DS, Knight SJ et al. Patient decision AIDS for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin 2009; 59: 379-390.
50. Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst 2009; 101: 1216-1220.
51. Elwyn G, O'Connor A, Stacey D et al. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ 2006; 333: 417.
52. Wolf AM, Wender RC, Etzioni RB et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70-98.
53. Newschaffer CJ, Otani K, McDonald MK, Penberthy LT. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 2000; 92: 613-621.
54. Brawley OW. Prostate cancer screening; is this a teachable moment? J Natl Cancer Inst 2009; 101: 1295-1297.